title: Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.
abstract: Deficiencies in DNA repair have been hypothesized to increase cancer risk and excess cancer incidence is a feature of inherited diseases caused by defects in DNA damage recognition and repair. We investigated, using a case-control design, whether the double-strand break repair gene polymorphisms RAD51 5' untranslated region -135 G > C, XRCC2 R188H G > A, and XRCC3 T241M C > T were associated with risk of breast or ovarian cancer in Australian women. Sample sets included 1,456 breast cancer cases and 793 age-matched controls ages under 60 years of age, 549 incident ovarian cancer cases, and 335 controls of similar age distribution. For the total sample and the subsample of Caucasian women, there were no significant differences in genotype distribution between breast cancer cases and controls or between ovarian cancer cases and combined control groups. The crude odds ratios (OR) and 95% confidence intervals (95% CI) associated with the RAD51 GC/CC genotype frequency was OR, 1.10; 95% CI, 0.80-1.41 for breast cancer and OR, 1.22; 95% CI, 0.92-1.62 for ovarian cancer. Similarly, there were no increased risks associated with the XRCC2 GA/AA genotype (OR, 0.98; 95% CI, 0.76-1.26 for breast cancer and OR, 0.93; 95% CI, 0.69-1.25 for ovarian cancer) or the XRCC3 CT/TT genotype (OR, 0.92; 95% CI, 0.77-1.10 for breast cancer and OR, 0.87; 95% CI, 0.71-1.08 for ovarian cancer). Results were little changed after adjustment for age and other measured risk factors. Although there was little statistical power to detect modest increases in risk for the homozygote variant genotypes, particularly for the rare RAD51 and XRCC2 variants, the data suggest that none of these variants play a major role in the etiology of breast or ovarian cancer.
authors.affiliation: Population and Clinical Sciences Division, Queensland Institute of Medical Research and University of Queensland, Brisbane, Queensland, Australia.
authors.forename: Penelope M
authors.initials: PM
authors.lastname: Webb
authors.forename: John L
authors.initials: JL
authors.lastname: Hopper
authors.forename: Beth
authors.initials: B
authors.lastname: Newman
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Chen
authors.forename: Livia
authors.initials: L
authors.lastname: Kelemen
authors.forename: Graham G
authors.initials: GG
authors.lastname: Giles
authors.forename: Melissa C
authors.initials: MC
authors.lastname: Southey
authors.forename: Georgia
authors.initials: G
authors.lastname: Chenevix-Trench
authors.forename: Amanda B
authors.initials: AB
authors.lastname: Spurdle
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000235:genetics*; D011110:Polymorphism, Genetic; D051135:Rad51 Recombinase; D012307:Risk Factors
chemical_list: D004268:DNA-Binding Proteins; C110901:X-ray repair cross complementing protein 3; C113187:XRCC2 protein, human; C495153:RAD51 protein, human; D051135:Rad51 Recombinase